Avinger Full Year 2022 Earnings: US$4.36 loss per share (vs US$4.57 loss in FY 2021)

Avinger (NASDAQ:AVGR) Full Year 2022 Results

Key Financial Results

• Revenue: US$8.27m (down 18% from FY 2021).
• Net loss: US$27.2m (loss widened by 26% from FY 2021).
• US$4.36 loss per share.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Avinger shares are down 5.8% from a week ago.

Risk Analysis

Before we wrap up, we've discovered 3 warning signs for Avinger that you should be aware of.

What are the risks and opportunities for Avinger?

NasdaqCM:AVGR

Avinger

Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) in the United States and internationally.Show more

View Full Analysis

Risks

• Has less than 1 year of cash runway

• Shareholders have been substantially diluted in the past year

• Does not have a meaningful market cap ($7M)

View all Risks and Rewards

Share Price

Market Cap

1Y Return

View Company Report

Further research on
Avinger

ValuationFinancial HealthInsider TradingManagement Team

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.